Mike Biaga
Vice President of Investor Relations and Communications
Replay available
Harrow, Inc. (HROW) Q1 2026 Earnings Call
Harrow, Inc. (NASDAQ: HROW) Q1 2026 earnings conference call, held 2026-05-12. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Mark L. Baum
Chief Executive Officer
Thomas Flatton
Analyst, Lake Street Capital Markets
Tom Schrader
Analyst, VTIG
Andrew Bull
President and Chief Financial Officer
Pat Sullivan
Chief Commercial Officer
Amir Shojai
Chief Scientific Officer
Tamar Abenico
Analyst, Cantor
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Harrow, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.259 Good morning and welcome to HARO's first quarter 2026 earnings conference 00:00:05.259 -- 00:00:11.007 call. My name is Michelle and I will be your operator for today's call. 00:00:11.007 -- 00:00:15.574 At this time all participants are in a listen only mode. 00:00:15.574 -- 00:00:19.439 Later we will conduct a question and answer session. 00:00:19.439 -- 00:00:23.666 As a reminder this conference is being recorded. 00:00:23.666 -- 00:00:28.756 I would now like to turn the call over to to Mike Biaga, 00:00:28.756 -- 00:00:32.702 Vice President of Investor Relations and Communications 00:00:32.702 -- 00:00:36.224 for HARO. Please go ahead. 00:00:37.088 -- 00:00:41.954 Thank you, operator. Good morning, and welcome to HARO's first quarter 2026 earnings 00:00:41.954 -- 00:00:47.321 conference call. My name is Mike Biaga, Vice President of Investor Relations and Communications, 00:00:47.321 -- 00:00:50.285 and I'm excited to be introducing today's call. 00:00:50.285 -- 00:00:54.451 The company's remarks may include forward-looking statements within the meaning of federal 00:00:54.451 -- 00:00:59.384 securities laws. Forward-looking statements are subject to numerous risks and uncertainties, 00:00:59.384 -- 00:01:04.031 many of which are beyond HARO's control, including risks and uncertainties described 00:01:04.031 -- 00:01:08.919 from time to time in its SEC filings, such as the risks and uncertainties related to 00:01:08.919 -- 00:01:13.946 the company's ability to make commercially available its FDA-approved products and compounded 00:01:13.946 -- 00:01:18.674 formulations and technologies and FDA approval of certain drug candidates in a timely 00:01:18.674 -- 00:01:23.290 manner or at all. For a list and description of those risks...